Open an account

Compugen

CGEN · NASDAQ

$2.14+$0.17 (+8.63%)TodayMarket closed ·
Prev close $1.97

About CGEN

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Employees
75
Headquarters
Holon
Listed
Aug 1, 2000
Sector
Health Care
Industry
Biotechnology
Website
cgen.com

CGEN key statistics

Market cap
202.72M
Price-earnings ratio
5.18
Dividend yield
—
Average volume
185.08K
Volume
923.30K
Open price
$1.97
High today
$2.18
Low today
$1.96
52 Week high
$3.24
52 Week low
$1.43

Compugen (CGEN) at a glance

Compugen (CGEN) last traded at $2.14, with a market cap of 202.72M and a price-to-earnings ratio of 5.18.

Today the stock has traded between $1.96 and $2.18. The current price is 9.2% above the day's low and 1.8% below its high.

Volume so far is 923.30K shares, above the average of 185.08K shares a day.

Over the past year Compugen has ranged from $1.43 to $3.24, and now sits 39% of the way up that range.

Compugen met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.0816.

The average analyst price target is $4.69, 119.3% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $4.69
Low
$4.04
Now
$2.14
High
$6.30

CGEN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 370.5% on average.

  1. Q3 FY24: reported $0.01 per share against an estimate of $0.1074
  2. Q4 FY24: reported -$0.07 per share against an estimate of $0.0748
  3. Q1 FY25: reported -$0.08 per share against an estimate of -$0.0561
  4. Q2 FY25: reported -$0.08 per share against an estimate of -$0.0663
  5. Q3 FY25: reported -$0.07 per share against an estimate of -$0.0884
  6. Q4 FY25: reported $0.60 per share against an estimate of $0.051
  7. Q1 FY26: reported -$0.08 per share against an estimate of -$0.074
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.0816

CGEN news

  • Press releasePRNewswire

    Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference

  • Press releasePRNewswire

    Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026

  • Press releasePRNewswire

    Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releasePRNewswire

    Compugen Reports Second Quarter 2026 Results

  • Press releasePRNewswire

    Compugen to Participate in BTIG Biotechnology Conference 2026

  • Press releasePRNewswire

    Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026

  • Press releasePRNewswire

    Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress

  • Press releasePRNewswire

    Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

Similar companies

Companies in the same industry as Compugen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.